Location & Type arrow_drop_up Concepts arrow_drop_down Orgs arrow_drop_down
Filter by Concept
#1
Changchun Deng
Changchun Deng
Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York
Known for star star star star star
Follicular Lymphoma | Phase Carfilzomib | Inhibitor Tgr-1202 | Relapsed Refractory
#2
I Divisione di Malattie Infettive, Ospedale Luigi
I Divisione di Malattie Infettive, Ospedale Luigi
Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy
Known for star star star star star_half
Rituximab Lenalidomide | Relapsed Refractory | Follicular Lymphoma | Phase Iii

#3
Translational Cancer Medicine, Surgical Oncology,
Translational Cancer Medicine, Surgical Oncology,
Medical Oncology, Istituto di Candiolo-IRCCS-Fondazione Piemontese per la Ricerca sul Cancro-Onlus, Candiolo, Italy
Known for star star star star star_half
Breast Cancer | Phase Iii | Metastatic Colorectal | Hormonal Therapy
#4
Maria Alma Rodriguez
Maria Alma Rodriguez
Division of Medicine, Lymphoma Section, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Known for star star star star star_border
Radiation Therapy | Follicular Lymphoma | Response Rate | Denileukin Diftitox
#5
Julie Marie Vose
Julie Marie Vose
From the Section of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center the Department of Internal Medicine, Omaha Veterans Affairs ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | Speakers Bureau
#6
Krimo Bouabdallah
Krimo Bouabdallah
CHU Bordeaux, Service d’Hématologie et Thérapie Cellulaire, Bordeaux, France
Known for star star star star star_border
Advisory Committees | Entitys Board | Speakers Bureau | Intensive Chemotherapy
#7
Anca A. Prica
Anca A. Prica
From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite ...
Known for star star star star star_border
Hematologic Malignancies | Advisory Committees | Drug Wastage | Entitys Board
#8
Nicolas Ketterer
Nicolas Ketterer
Reprints: Philippe Moreau, Hematology Department, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, 44093 Nantes cedex 01, France; e-mail: philippe.moreau{at}chu-nantes.fr.
Known for star star star star star_border
Follicular Lymphoma | Response Rate | Single Agent | Event-Free Survival
#9
Silvia Mappa
Silvia Mappa
Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy,
Known for star star star star star_border
Chronic Liver | Bay 80-6946 | Burkitt Lymphoma | Phase 2
#10
Martin Mohren
Martin Mohren
From University Hospital Magdeburg, Division of Cardiology (A.G., M.A., A.A., H.U.K.), Institute of Experimental Internal Medicine (U.L., C.R), Division of Hematology/Oncology ...
Known for star star star star star_border
Acute Leukaemia | Capillary Blood Count | Corticosteroid Injection | Willebrand Factor
#11
David A. MacDonald
David A. MacDonald
The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
Known for star star star star star_border
Follicular Lymphoma | Subcutaneous Rituximab | Speakers Bureau | Inotuzumab Ozogamicin
#12
Naoki Takata
Naoki Takata
Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital, Kakogawa, Japan
Known for star star star star star_border
Oro-Cervical Region | Vertical Distraction Osteogenesis | Transport Segment | Lingual Inclination
#13
Kevin R. Imrie
Kevin R. Imrie
Department of Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Department of Medicine, University of Toronto, Toronto, ON, Canada
Known for star star star star star_border
Follicular Lymphoma | Autologous Bone Marrow Transplantation | Molecular Remission | Ovarian Function
#14
Stacey Kalambakas
Stacey Kalambakas
Clinical Research Science, Celgene Corporation, Summit, United States
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#15
Martin P Dreyling
Martin P Dreyling
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University (LMU), Munich, Germany., CorrespondenceMartin.Dreyling@med.uni-muenchen.de, ...
Known for star star star star star_border
Mantle Lymphoma | Molecular Remission | Advanced Stage | European Mcl Network
#16
Roswitha Forstpointner
Roswitha Forstpointner
Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany
Known for star star star star star_border
Follicular Lymphoma | Rituximab Maintenance | Response Duration | Stem Cells
#17
Cathy E. Nolan
Cathy E. Nolan
Authors' Affiliations: 1Johns Hopkins University; 2National Cancer Institute, Baltimore, Maryland; 3University of California Los Angeles, Los Angeles, California; 4Northwest ...
Known for star star star star star_border
Bcl-2 Inhibitor | Solid Tumors | Commercial Income | Stock Owner

 

Recently Asked Questions

View all FAQs

Many women suffer from period insomnia, which is difficulty sleeping during the week before their period. There are a number of possible causes of this...

 

Spinal Cord Tumor A spinal cord tumor is a mass or growth that develops within the spinal cord or the tissues surrounding it. These tumors can be either benign (noncancerous)...

 

Sevelamer Carbonate Sevelamer carbonate is a medication used to treat high levels of phosphate in the blood. It works by binding to phosphate in the intestine and preventing it...

 

Foot Fracture A fracture is a break in the bone. A foot fracture is a break that occurs in any of the bones in the foot. Fractures can occur from direct trauma to the...

 

Pseudo Tumor A pseudo tumor is a type of growth that can occur in the body. It is not a true tumor, as it is not made up of abnormal cells. However, it can still cause...

 

Multicentric Phase I/ii Study For The Efficacy Of A Combination Of Rituximab,...

[ CLINICAL_TRIAL ] ... for indolent lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with ...
Known for star star star star star
Indolent Lymphoma | Gemcitabine Oxaliplatin | Phase Combination | Rituximab Relapsed

A Phase Ii Multicenter Non-Randomized Study To Assess Safety, Toxicity And...

[ CLINICAL_TRIAL ] ... sensitive indolent non-follicular and mantle cell non-Hodgkin's lymphoma. Despite of the availability of treatment for this disease, this study is justified because no known therapies are
Known for star star star star star
Refractory Indolent | Hodgkin Lymphoma | Bortezomib Rituximab | Assess Safety

A Phase 3, Double-Blind, Randomized Study To Compare The Efficacy And Safety Of...

[ CLINICAL_TRIAL ] ... Description Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are ...
Known for star star star star star_half
Indolent Lymphoma | Rituximab Lenalidomide | Marginal Zone | Immune Cells

A Phase I Trial Of Obinutuzumab In Combination With Venetoclax In Previously...

[ CLINICAL_TRIAL ] Follicular lymphoma (FL) is an indolent yet incurable lymphoma characterized by initial responses to standard therapies, invariably followed by shorter disease free intervals. Obinutuzumab, a ...
Known for star star star star star_border
Follicular Lymphoma | Obinutuzumab Combination | Cll Trial | Single Agent

A Phase I, Dose-Escalation Trial Of Rituxan And Bendamustine In Combination With...

[ CLINICAL_TRIAL ] ... non-Hodgkin lymphoma (NHL). BTK inhibitor PCI-32765 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, ...
Known for star star star star star_border
Bendamustine Pci-32765 | Btk Inhibitor | Escalation Trial | Cancer Cells

A Phase 1b/2 Study Of Duvelisib And Venetoclax In Subjects With Relapsed Or...

[ CLINICAL_TRIAL ] ... or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Phosphoinositide 3-kinase (PI3K) inhibitor. The Phase 2 portion of the study will preliminarily ...
Known for star star star star star_border
Lymphocytic Lymphoma | Phase Duvelisib | Leukemia Small | Venetoclax Relapsed

A Phase 1 Study Of Nkx019, A Cd19 Chimeric Antigen Receptor Natural Killer (Car...

[ CLINICAL_TRIAL ] ... non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL) Detailed Description This is a dose-finding study of NKX019 and will be ...
Known for star star star star star_border
Receptor Natural | Chimeric Antigen | Phase Nkx019 | Safety Tolerability

A Phase 2, Open-Label, Multicenter Study Of The Safety And Efficacy Of Tak-007 In...

[ CLINICAL_TRIAL ] ... Non-Hodgkin Lymphoma.The main aim of Part 2 is to learn if lymphomas are reduced or gone after treatment withTAK-007 in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma or ...
Known for star star star star star_border
Hodgkin Lymphoma | Tak-007 Relapsed | Escalation Expansion | Aim Check

A Phase 2, Open-Label Study Evaluating The Efficacy, Safety, Tolerability, And...

[ CLINICAL_TRIAL ] ... cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström ...
Known for star star star star star_border
Hematologic Malignancies | Relapsed Refractory | Evaluate Entospletinib | Primary Objective

A Phase 1b Open-Label Study To Evaluate The Safety And Efficacy Of Cc-122 In...

[ CLINICAL_TRIAL ] CC-122-NHL-001 study is a multicenter, open-label, phase Ib study with dose escalation and expansion parts. It evaluates the safety, tolerability and clinical pharmacokinetics of CC-122 in ...
Known for star star star star star_border
Safety Cc-122 | Combination Obinutuzumab | Expansion Phase | Refractory Relapsed